Search

Displaying results 6771 - 6780 of 10000 in total
  1. Drug

    Rineterkib

    go.drugbank.com/drugs/DB17560
    Investigational

    Ruxolitinib Combinations in Myelofibrosis Patients). … Rineterkib is an inhibitor of extracellular signal-regulated kinase (ERK) being investigated in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel

    Synonyms: 4-(3-amino-6-((1s,3s,4s)-3-fluoro-4-hydroxycyclohexyl)-2-pyrazinyl)-n-((1s)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl)-2-fluorobenzamide, Benzamide, 4-(3-amino-6-((1s,3s,4s)-3-fluoro-4-hydroxycyclohexyl)-2-pyrazinyl)-n-((1s)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl)-2-fluoro-
  2. Drug

    Aminoimidazole carboxamide

    go.drugbank.com/drugs/DB06143
    Investigational

  3. Drug

    Semaxanib

    go.drugbank.com/drugs/DB06436
    Investigational

  4. Drug

    Fipamezole

    go.drugbank.com/drugs/DB06585
    Investigational

  5. Drug

    Freselestat

    go.drugbank.com/drugs/DB03925
    Experimental

  6. Drug

    TRU-015

    go.drugbank.com/drugs/DB05580
    Investigational

  7. Drug

    CRD5

    go.drugbank.com/drugs/DB05587
    Experimental

  8. Drug

    Pemoline

    go.drugbank.com/drugs/DB01230
    ApprovedIllicitWithdrawn

    In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.

  9. Drug

    Methapyrilene

    go.drugbank.com/drugs/DB04819
    ApprovedWithdrawn

    Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.

    Synonyms: N-(α-pyridyl)-N-(α-thenyl)-N',N'-dimethylethylenediamine, N,N-dimethyl-N'-pyrid-2-yl-N'-2-thenylethylenediamine
  10. Drug

    RGN6024

    go.drugbank.com/drugs/DB33059
    Experimental

    cells, and suppresses tumor growth in glioblastoma xenograft models. … Reglagene announced FDA orphan drug designation for glioblastoma in 2024. RGN6024 remains investigational and is not an approved drug.